English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the zaia usage as premium feature

ZAIA

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the access of premium content as premium feature

Premium Content

Zendy Tools

Zendy Open

Background  Timely thrombolytic therapy can improve stroke outcomes. Nevertheless, the ability of US hospitals to meet guidelines for intravenous tissue plasminogen activator ( tPA ) remains suboptimal. What is unclear is whether hospitals accurately perceive their rate of  tPA  “door‐to‐needle” ( DTN ) time within 60 minutes and how  DTN  rates compare across different hospitals.    Methods and Results   DTN  performance was defined by the percentage of treated patients who received  tPA  within 60 minutes of arrival. Telephone surveys were obtained from staff at 141 Get With The Guidelines hospitals, representing  top, middle , and  low   DTN  performance. Less than one‐third (29.1%) of staff accurately identified their  DTN  performance. Among middle‐ and low‐performing hospitals (n=92), 56 sites (60.9%) overestimated their performance; 42% of middle performers and 85% of low performers overestimated their performance. Sites that overestimated tended to have lower annual volumes of  tPA  administration (median 8.4 patients [25th to 75th percentile 5.9 to 11.8] versus 10.2 patients [25th to 75th percentile 8.2 to 17.3],  P =0.047), smaller percentages of eligible patients receiving  tPA  (84.7% versus 89.8%,  P =0.008), and smaller percentages of  DTN  ≤60 minutes among treated patients (10.6% versus 16.6%,  P =0.002).    Conclusions  Hospitals often overestimate their ability to deliver timely  tPA  to treated patients. Our findings indicate the need to routinely provide comparative provider performance rates as a key step to improving the quality of acute stroke care.

Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke